【Scinopharm】February 2026 Revenue Reaches NT$207 Million (YoY +26.3%)
NQ Score
67/100
N1 Content Completeness
7
AI Summary (NQ-processed)
Scinopharm (1789) announced its February 2026 monthly revenue of NT$207 million, a significant year-on-year increase of 26.3%. As a globally important active pharmaceutical ingredient (API) supplier, this revenue growth reflects the stable increase in customer orders in high-barrier fields such as cancer drugs.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was Scinopharm's revenue for February 2026?
- A: Scinopharm's revenue for February 2026 reached NT$207 million, which is equivalent to 207,454 thousand NTD.
- Q: How did Scinopharm's February 2026 revenue compare to the same month last year?
- A: Scinopharm's revenue in February 2026 experienced a significant year-on-year increase of +26.3% compared to February 2025.
- Q: What is the company code for Scinopharm?
- A: The company code assigned to Scinopharm is 1789, as indicated in the provided financial data.
- Q: In which industry sector does Scinopharm operate?
- A: Scinopharm is a company that operates within the Biotechnology and Medical Industry sector, as stated in the article.
- Q: What was the specific revenue figure for Scinopharm in February 2026?
- A: The precise revenue figure for Scinopharm in February 2026 was 207,454 thousand NTD, also reported as NT$207 million.